Bayer Enters Pre-Results Blackout With Buy Calls Intact and Forecasts Softening

Bayer's third-quarter report is still weeks away, but the company has now entered the quiet period ahead of its November 3 disclosure — a stretch in which fresh corporate news typically dries up and the market is left to weigh what it already knows. For the German life-sciences group, that means two very different narratives are running side by side: a steady stream of pipeline and investment announcements, and a set of analyst estimates that has been quietly trimmed.

UBS reaffirmed its "Buy" rating on Bayer, keeping a price target of EUR 62, according to media reports. Analyst Matthew Weston anchored his case in the outlook for the agricultural division, where he sees intact trends stretching through 2026 and 2027, alongside momentum in the pharmaceuticals business. His view rests on both units working together rather than on a single product or a standalone recovery in crop science. The confirmation is a restatement of an existing positive stance, not a fresh upgrade.

A Split Screen on Expectations

That constructive call sits opposite a more cautious read on the near term. On Tuesday, media coverage highlighted lower analyst expectations for the third quarter, with timing effects in the agricultural business cited as a factor. Such revisions are neither reported results nor an automatic downgrade of the stock.

JPMorgan had already staked out a similar position earlier. On October 1, the US bank left Bayer at "Overweight" with a price target of EUR 61. Analyst Richard Vosser described early market expectations for the third quarter as too high, attributing the gap primarily to scheduling shifts in the agriculture segment. The distinction matters for investors: a timing-related deferral within the normal course of business is a different animal from a fundamental deterioration, though only the published figures will show whether that explanation holds up.

Pipeline News Sets the Backdrop

Behind the positive analyst framing is a run of pharmaceutical developments. The FDA has accepted Bayer's supplemental application for finerenone, marketed as Kerendia, covering adults with chronic kidney disease who do not have diabetes. According to the company, the filing draws on positive results from the Phase III FIND-CKD trial. Acceptance of the application is explicitly not an approval for that use.

Clinical work is advancing as well. Bayer subsidiary Vividion Therapeutics expanded development of its WRN inhibitor VVD-214 with a Phase II combination study in first-line patients with advanced colorectal cancer — a development step, not a demonstrated treatment success.

Roughly two weeks ago, Bayer also announced a USD 2.2 billion investment in a new pharmaceutical production site in New Albany, Ohio, expected to create around 600 jobs. That project is a declared intention, not a completed expansion.

The Date That Settles the Argument

Bayer plans to publish its third-quarter 2026 results on November 3, with the release scheduled for 07:30 CET and an investor video conference to follow at 14:00 CET. That morning will provide the first hard yardstick for the debate now playing out in research notes — a direct comparison between actual business performance and the recently pared-back estimates.

Until then, the positive pharmaceutical headlines serve as context rather than a substitute for results. Intact agricultural trends, ongoing clinical development and investment plans all support the longer-term picture, but none of them answers how the past quarter actually unfolded, and none replaces a regulatory decision or a reported earnings figure.